Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653482 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
A Phase 4 study, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 263
- Enrollment target
NCT02653482 is a Phase 4 study that has completed, run by Saint Luke's Health System. The registered enrollment target is 263 participants.
The verdict
NCT02653482, a Phase 4 study, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 263 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.
Interventions
- DRUG Dapagliflozin
- DRUG Dapagliflozin matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2016-03-03 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653482
The ClinicalTrials.gov registry entry for NCT02653482 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint Luke's Health System, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02653482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02653482 about?
NCT02653482 is a clinical study titled "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure". The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.
What is the current status of trial NCT02653482?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 263 participants. The study started on 2016-03-03. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02653482?
The interventions under investigation include: Dapagliflozin (DRUG), Dapagliflozin matching placebo (DRUG).
Who is sponsoring clinical trial NCT02653482?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.